Jan 09, 2024 / 05:00PM GMT
Calvin Alexander Sternick - JPMorgan Chase & Co, Research Division - Analyst
Hi. Good morning. My name is Cal Sternick. I'm the managed Medicaid and facilities analyst here at JPMorgan. I'm pleased to have with us here, Centene's CEO, Sarah London; and CFO, Drew Asher; for a fireside chat this morning. I'm going to turn it over to Sarah for a few introductory remarks, and then we'll move on to Q&A. Sarah?
Sarah M. London - Centene Corporation - CEO & Director
Thanks, Cal. Good morning. Happy new year. Glad to be back kicking off the year at JPMorgan. We obviously had our Investor Day just a few weeks ago in December and covered quite a lot of ground there, including reaffirming our 2023 guidance of at least $6.60 and then sharing 2024 guidance of greater than $6.70. So with that as a backdrop, I thought I might just provide a few updates since then, and then we can dive into questions.
So one of the things we talked about at Investor Day was that we were planning for one of our major value creation milestones at the end of 2023. And so while
Centene Corp at JPMorgan Healthcare Conference Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers